Cargando…
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK sam...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048619/ https://www.ncbi.nlm.nih.gov/pubmed/33145788 http://dx.doi.org/10.1002/jcph.1771 |
_version_ | 1783679262117593088 |
---|---|
author | Luo, Man (Melody) Usmani, Saad Z. Mateos, Maria‐Victoria Nahi, Hareth Chari, Ajai San‐Miguel, Jesus Touzeau, Cyrille Suzuki, Kenshi Kaiser, Martin Carson, Robin Heuck, Christoph Qi, Ming Zhou, Honghui Sun, Yu‐Nien Parasrampuria, Dolly A. |
author_facet | Luo, Man (Melody) Usmani, Saad Z. Mateos, Maria‐Victoria Nahi, Hareth Chari, Ajai San‐Miguel, Jesus Touzeau, Cyrille Suzuki, Kenshi Kaiser, Martin Carson, Robin Heuck, Christoph Qi, Ming Zhou, Honghui Sun, Yu‐Nien Parasrampuria, Dolly A. |
author_sort | Luo, Man (Melody) |
collection | PubMed |
description | We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK samples from 742 patients (DARA 1800 mg subcutaneously, n = 487 [monotherapy, n = 288; combination therapy, n = 199]; DARA 16 mg/kg intravenously, n = 255 [all monotherapy, in COLUMBA]; age, 33‐92 years; weight, 28.6‐147.6 kg). Subcutaneous and intravenous DARA monotherapies were administered once every week for cycles 1‐2, once every 2 weeks for cycles 3‐6, and once every 4 weeks thereafter (1 cycle is 28 days). The subcutaneous DARA combination therapy was administered with the adaptation of corresponding standard‐of‐care regimens. PK samples were collected between cycle 1 and cycle 12. Among monotherapy studies, throughout the treatment period, subcutaneous DARA provided similar/slightly higher trough concentrations (C(trough)) versus intravenous DARA, with lower maximum concentrations and smaller peak‐to‐trough fluctuations. The PK profile was consistent between subcutaneous DARA monotherapy and combination therapies. The exposure‐response relationship between daratumumab PK and efficacy or safety end points was similar for subcutaneous and intravenous DARA. Although the ≤65‐kg subgroup reported a higher incidence of neutropenia, no relationship was found between the incidence of neutropenia and exposure, which was attributed, in part, to the preexisting imbalance in neutropenia between subcutaneous DARA (45.5%) and intravenous DARA (19%) in patients ≤50 kg. A flat relationship was observed between body weight and any grade and at least grade 3 infections. The results support the DARA 1800‐mg subcutaneous flat dose as an alternative to the approved intravenous DARA 16 mg/kg. |
format | Online Article Text |
id | pubmed-8048619 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80486192021-04-19 Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients Luo, Man (Melody) Usmani, Saad Z. Mateos, Maria‐Victoria Nahi, Hareth Chari, Ajai San‐Miguel, Jesus Touzeau, Cyrille Suzuki, Kenshi Kaiser, Martin Carson, Robin Heuck, Christoph Qi, Ming Zhou, Honghui Sun, Yu‐Nien Parasrampuria, Dolly A. J Clin Pharmacol Exposure Response We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK samples from 742 patients (DARA 1800 mg subcutaneously, n = 487 [monotherapy, n = 288; combination therapy, n = 199]; DARA 16 mg/kg intravenously, n = 255 [all monotherapy, in COLUMBA]; age, 33‐92 years; weight, 28.6‐147.6 kg). Subcutaneous and intravenous DARA monotherapies were administered once every week for cycles 1‐2, once every 2 weeks for cycles 3‐6, and once every 4 weeks thereafter (1 cycle is 28 days). The subcutaneous DARA combination therapy was administered with the adaptation of corresponding standard‐of‐care regimens. PK samples were collected between cycle 1 and cycle 12. Among monotherapy studies, throughout the treatment period, subcutaneous DARA provided similar/slightly higher trough concentrations (C(trough)) versus intravenous DARA, with lower maximum concentrations and smaller peak‐to‐trough fluctuations. The PK profile was consistent between subcutaneous DARA monotherapy and combination therapies. The exposure‐response relationship between daratumumab PK and efficacy or safety end points was similar for subcutaneous and intravenous DARA. Although the ≤65‐kg subgroup reported a higher incidence of neutropenia, no relationship was found between the incidence of neutropenia and exposure, which was attributed, in part, to the preexisting imbalance in neutropenia between subcutaneous DARA (45.5%) and intravenous DARA (19%) in patients ≤50 kg. A flat relationship was observed between body weight and any grade and at least grade 3 infections. The results support the DARA 1800‐mg subcutaneous flat dose as an alternative to the approved intravenous DARA 16 mg/kg. John Wiley and Sons Inc. 2020-11-03 2021-05 /pmc/articles/PMC8048619/ /pubmed/33145788 http://dx.doi.org/10.1002/jcph.1771 Text en © 2020 Janssen Pharmaceuticals. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Exposure Response Luo, Man (Melody) Usmani, Saad Z. Mateos, Maria‐Victoria Nahi, Hareth Chari, Ajai San‐Miguel, Jesus Touzeau, Cyrille Suzuki, Kenshi Kaiser, Martin Carson, Robin Heuck, Christoph Qi, Ming Zhou, Honghui Sun, Yu‐Nien Parasrampuria, Dolly A. Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients |
title | Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients |
title_full | Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients |
title_fullStr | Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients |
title_full_unstemmed | Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients |
title_short | Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients |
title_sort | exposure‐response and population pharmacokinetic analyses of a novel subcutaneous formulation of daratumumab administered to multiple myeloma patients |
topic | Exposure Response |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048619/ https://www.ncbi.nlm.nih.gov/pubmed/33145788 http://dx.doi.org/10.1002/jcph.1771 |
work_keys_str_mv | AT luomanmelody exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT usmanisaadz exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT mateosmariavictoria exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT nahihareth exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT chariajai exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT sanmigueljesus exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT touzeaucyrille exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT suzukikenshi exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT kaisermartin exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT carsonrobin exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT heuckchristoph exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT qiming exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT zhouhonghui exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT sunyunien exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients AT parasrampuriadollya exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients |